Fortress Biotech, Inc. — Rendiconto Finanziario Trimestrale (NASDAQ:FBIO)

Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche Dividendi

Trimestrale Annuale

Market Capitalization 93.01 M
Employee 78
Founded 2006
CEO Lindsay Rosenwald
Website www.fortressbiotech.com
Headquarter Delaware, United States
FIGI BBG001J2MFH6
Industry Biotecnologia

Ricavi totali

Utile netto

Utile base per azione (EPS base)

Debito totale

Liquidità libera

Disponibilità liquide e mezzi equivalenti

Rapporto prezzo/utili

0.86

Rapporto prezzo/fatturato

1.34

Fortress Biotech, Inc. - Common Stock

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

FBIO

Financials

Fortress Biotech, Inc. - Common Stock

Notizie

Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO)

Relazione sugli utili: Journey Medical Q1 2026 segna +21% nei ricavi

Avenue Therapeutics licenses ATX-04 for Pompe disease treatment

Fortress Biotech Stock: The PRV Catalyst That Could Reprice This Microcap (NASDAQ:FBIO)

Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes

Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums

Centene Expands Palliative Care Access in Ohio Through Tuesday Health

FDA approva il primo trattamento per la malattia di Menkes nei bambini

FDA approves first treatment for Menkes disease in children

La FDA fissa una nuova data PDUFA per la terapia di Fortress Biotech contro la malattia di Menkes

FDA sets new PDUFA date for Fortress Biotech’s Menkes disease therapy

Fortress Biotech richiede la ripresentazione della NDA per il trattamento della malattia di Menkes